Loading...
•
Jun 30, 2022
Tenaya Therapeutics Q2 2022 Earnings Report
Reported financial results for the second quarter and provided a corporate update.
Key Takeaways
Tenaya Therapeutics reported its Q2 2022 financial results, highlighting progress in becoming a fully integrated clinical-stage company. The company is on track with IND submissions for TN-201 and TN-301 in the second half of 2022 and launched its Genetic Medicines Manufacturing Center.
Remains on track with its Investigational New Drug (IND) submission plans for TN-201 to the U.S. Food and Drug Administration (FDA) in the second half of 2022.
Remains on track with its IND submission plans for TN-301 to the FDA in the second half of 2022.
Tenaya intends to support the establishment of a global natural history study of ARVC in 2022 and expects to submit an IND application for TN-401 to the FDA in 2023.
In June, Tenaya announced the operational launch of its Genetic Medicines Manufacturing Center in Union City, California.
Tenaya Therapeutics
Tenaya Therapeutics
Forward Guidance
Tenaya expects current cash, cash equivalents and investments in marketable securities will be sufficient to fund its current operating plan at least into the second half of 2023.